We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of IBS-C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05643534
Recruitment Status : Recruiting
First Posted : December 8, 2022
Last Update Posted : December 8, 2022
Sponsor:
Information provided by (Responsible Party):
Ardelyx

Brief Summary:
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome With Constipation (IBS-C) Drug: Tenapanor 50 MG Drug: Tenapanor 25 mg bid Drug: Placebo Phase 3

Detailed Description:

This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo.

During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Actual Study Start Date : November 15, 2022
Estimated Primary Completion Date : August 29, 2024
Estimated Study Completion Date : October 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Experimental: Tenpanor 50 mg BID
Patients will be randomized to receive 50 mg tenapanor twice daily
Drug: Tenapanor 50 MG
Participants will receive tenapanor 50 mg BID (total of 100 mg daily)

Experimental: Tenpanor 25 mg BID
Patients will be randomized to receive 25 mg tenapanor twice daily
Drug: Tenapanor 25 mg bid
Participants will receive tenapanor 25 mg BID (total of 50 mg daily)

Placebo Comparator: Placebo Comparator
Patients will be randomized to receive matching placebo twice daily
Drug: Placebo
Participants will be randomized to receive matching placebo




Primary Outcome Measures :
  1. 6/12-week APS (abdominal pain and SBM) +2 response [ Time Frame: 12 weeks ]

    6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for ≥6 out of the 12 weeks of the RTP.

    • The weekly SBM +2 response is defined as having an increase of ≥2 from baseline in the average weekly SBM frequency for a given week
    • The weekly abdominal pain response is defined as having ≥30% reduction from baseline in the average weekly abdominal pain score for a given week


Secondary Outcome Measures :
  1. 6/12-week SBM +2 response [ Time Frame: 12 weeks ]
    6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for ≥6 out of the 12 weeks of the RTP

  2. 6/12-week abdominal pain response [ Time Frame: 12 weeks ]
    6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for ≥6 out of the 12 weeks of the RTP

  3. Change from baseline in average weekly SBM frequency [ Time Frame: 12 weeks ]
    Change from baseline in average weekly SBM frequency

  4. Change from baseline in average weekly stool consistency score [ Time Frame: 12 weeks ]
    Change from baseline in average weekly stool consistency score

  5. Change from baseline in average weekly abdominal pain score [ Time Frame: 12 weeks ]
    Change from baseline in average weekly abdominal pain score

  6. Overall use of rescue medication [ Time Frame: 12 weeks ]
    Overall use of rescue medication



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥12 and <18 years old
  • Patient weighs ≥18 kg at the time the patient provides written assent
  • Females of child-bearing potential must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate contraception (including abstinence).
  • Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C
  • Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  • Patient meets the entry criteria assessed during the 2-week Screening period.
  • Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  • Patient must provide written assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures

Exclusion Criteria:

  • Functional diarrhea as defined by Rome IV child/adolescent criteria
  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria
  • History of non-retentive fecal incontinence.
  • Required manual disimpaction any time prior to randomization (after consent);
  • Has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process
  • Patient has any of the following conditions:

    • Celiac disease, or positive serological test for celiac disease
    • Cystic fibrosis
    • Hypothyroidism that is untreated or treated with thyroid hormone
    • Down's syndrome or any other chromosomal disorder
    • Active anal fissure
    • Anatomic malformations (eg, imperforate anus)
    • Intestinal nerve or muscle disorders (eg, Hirschprung disease)
    • Neuropathic conditions (eg, spinal cord abnormalities)
    • Lead toxicity, hypercalcemia
    • Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device)
    • Inflammatory bowel disease
    • Childhood functional abdominal pain syndrome
    • Childhood functional abdominal pain;
    • Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    • Lactose intolerance that is associated with abdominal pain or discomfort
    • History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit.)
    • History of diabetic neuropathy.
  • Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.
  • Patient has had surgery that meets any of the following criteria:

    • Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit;
    • Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    • An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    • Other major surgery during the 30 days before the Screening Visit
  • History of alcohol or substance abuse
  • Participation in other clinical trials within 1 month prior to Screening
  • Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
  • If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05643534


Contacts
Layout table for location contacts
Contact: Jocelyn Tabora 510-745-1724 jtabora@ardelyx.com
Contact: Susan Edelstein, PhD 510-456-7741 sedelstein@ardelyx.com

Locations
Layout table for location information
United States, Alabama
G & L Research, LLC Recruiting
Foley, Alabama, United States, 36535
Contact: Christine Fuller       glresearch5@gmail.com   
Sponsors and Collaborators
Ardelyx
Investigators
Layout table for investigator information
Study Chair: David Rosenbaum, PhD Ardelyx
Layout table for additonal information
Responsible Party: Ardelyx
ClinicalTrials.gov Identifier: NCT05643534    
Other Study ID Numbers: TEN-01-304
First Posted: December 8, 2022    Key Record Dates
Last Update Posted: December 8, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ardelyx:
IBS-C
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Syndrome
Constipation
Disease
Pathologic Processes
Signs and Symptoms, Digestive
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases